Patents by Inventor Richard Charles Foitzik

Richard Charles Foitzik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 11911372
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 27, 2024
    Assignee: CTXT PTY LTD
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Compounds
    Publication number: 20220153710
    Abstract: A compound of formula (I), or a pharmaceutical salt thereof:
    Type: Application
    Filed: August 3, 2021
    Publication date: May 19, 2022
    Inventors: H. Rachel Lagiakos, Benjamin Joseph Morrow, Richard Charles Foitzik, Catherine Fae Hemley, Michelle Ang Camerino, Paul Anthony Stupple, Ylva Elisabet Bergman Bozikis, Scott Raymond Walker
  • Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family
    Publication number: 20210380548
    Abstract: A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1, and MOF.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 9, 2021
    Inventors: Benjamin Joseph Morrow, Richard Charles Foitzik, Michelle Ang Camerino, H. Rachel Lagiakos, Scott Raymond Walker, Ylva Elisabet Bergman Bozikis, Graeme Irvine Stevenson, Anthony Nicholas Cuzzupe, Paul Anthony Stupple
  • Compounds
    Publication number: 20210213004
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: July 15, 2021
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Tetrahydroisoquinoline derived PRMT5-inhibitors
    Patent number: 10647708
    Abstract: A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: May 12, 2020
    Assignee: CTXT PTY. LTD
    Inventors: Richard Charles Foitzik, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos
  • Compounds
    Publication number: 20200039945
    Abstract: A compound of formula (I), or a pharmaceutical salt thereof:
    Type: Application
    Filed: June 20, 2019
    Publication date: February 6, 2020
    Applicant: CTxT Pty Limited
    Inventors: Helen Rachel Lagiakos, Benjamin Joseph Morrow, Richard Charles Foitzik, Catherine Fae Hemley, Michelle Ang Camerino, Paul Anthony Stupple, Ylva Elisabet Bergman Bozikis, Scott Raymond Walker
  • Tetrahydroisoquinoline derived PRMT5-inhibitors
    Patent number: 10494376
    Abstract: A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 3, 2019
    Assignee: CTXT PTY. LTD.
    Inventors: Ylva Elisabet Bergman, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Graeme Irvine Stevenson, Paul Anthony Stupple
  • Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
    Patent number: 10005792
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 26, 2018
    Assignee: CTXT PTY. LTD.
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
    Patent number: 9856252
    Abstract: Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from: a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are ? to one another; L1 is selected from: (i) A1—O—CH2—A2; (ii) A1—CH2—O—A2; (iii) A1—C(?O)—NH—A2; (iv) A1—CH(OH)—A2; (v) A1—CH2—NH—C(?O)—A2; (vi) A1—S—CH2—A2; (vii) A1—CH2—S—A2; (viii) A1—CH2—A2; and (ix) A1—CH(CH3)—O—A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: January 2, 2018
    Assignee: Cancer Therapeutics CRC Pty Ltd
    Inventors: Paul Anthony Stupple, Scott Raymond Walker, Jo-Anne Pinson, Helen Rachel Lagiakos, Gillian Elizabeth Lunniss, Ian Peter Holmes, Alexandra Elizabeth Stupple, Ylva Elisabet Bergman, Richard Charles Foitzik, Wilhelmus Johannes Antonius Kersten, Michelle Ang Camerino
  • AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS
    Publication number: 20170313713
    Abstract: A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R1 and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: November 2, 2017
    Inventors: Ylva Elisabet Bergman, Romina Lessene, Danny Ganame, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Paul Anthony Stupple
  • TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS
    Publication number: 20170298075
    Abstract: A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 19, 2017
    Inventors: Ylva Elisabet Bergman, Richard Charles Foitzik, Benjamin Joseph Morrow, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos, John Feutrill, Graeme Irvine Stevenson, Paul Anthony Stupple
  • TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS
    Publication number: 20170283407
    Abstract: A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 5, 2017
    Inventors: Richard Charles Foitzik, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos
  • FAK inhibitors
    Patent number: 9421205
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: August 23, 2016
    Assignee: Cancer Therapeutics CRC PTY LTD.
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE
    Publication number: 20160222005
    Abstract: Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from: a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are ? to one another; L1 is selected from: (i) A1—O—CH2—A2; (ii) A1—CH2—O—A2; (iii) A1—C(?O)—NH—A2; (iv) A1—CH(OH)—A2; (v) A1—CH2—NH—C(?O)—A2; (vi) A1—S—CH2—A2; (vii) A1—CH2—S—A2; (viii) A1—CH2—A2; and (ix) A1—CH(CH3)—O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 4, 2016
    Inventors: Paul Anthony Stupple, Scott Raymond Walker, Jo-Anne Pinson, Helen Rachel Lagiakos, Gillian Elizabeth Lunniss, Ian Peter Holmes, Alexandra Elizabeth Stupple, Ylva Elisabet Bergman, Richard Charles Foitzik, Wilhelmus Johannes Antonius Kersten, Michelle Ang Camerino
  • VEGFR3 inhibitors
    Patent number: 9266864
    Abstract: This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: February 23, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Neil Choi, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • VEGFR3 inhibitors
    Patent number: 9238644
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 19, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • VEGFR3 INHIBITORS
    Publication number: 20160009686
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: January 14, 2016
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • Selective FAK inhibitors
    Patent number: 9174946
    Abstract: A compound of the formula (I): where R1 or R2 is a cycle, amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 3, 2015
    Assignee: Cancer Therapeutics CRC Pty LTD
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • Selective FAK inhibitors
    Patent number: 9120761
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2015
    Assignee: Cancer Therapeutics CRC PTY LTD
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Chol, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20150231135
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 20, 2015
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene